SignatureFD’s Verve Therapeutics VERV Stock Holding History

SignatureFD’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-196	Closed	-$2.2K	–	3489
2025 Q2	$2.2K	Sell	196 -2,771	-93%	-$15.8K	﹤0.01%	2840
2025 Q1	$13.6K	Buy	2,967 +1,078	+57%	+$7.22K	﹤0.01%	2245
2024 Q4	$10.7K	Sell	1,889 -165	-8%	-$931	﹤0.01%	2344
2024 Q3	$9.94K	Buy	2,054 +1,384	+207%	+$8.04K	﹤0.01%	2339
2024 Q2	$3.27K	Buy	670 +505	+306%	+$3.17K	﹤0.01%	2635
2024 Q1	$2.19K	Sell	165 -35	-18%	-$464	﹤0.01%	2781
2023 Q4	$2.79K	Buy	200 +153	+326%	+$1.9K	﹤0.01%	2675
2023 Q3	$623	Buy	+47	New	+$757	﹤0.01%	2995

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SignatureFD's VERV Position: Q3 2025 in Review

SignatureFD sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 196 shares — an estimated $2.2K sold.

SignatureFD first reported a position in VERV in Q3 2023 and held it in 8 quarters. The position peaked at $13.6K in Q1 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

SignatureFD reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
SignatureFD sold 196 Verve Therapeutics shares in Q3 2025, an estimated $2.2K.
SignatureFD first reported a position in Verve Therapeutics in Q3 2023 and held it in 8 quarters.
SignatureFD's Verve Therapeutics position peaked at $13.6K in Q1 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on SignatureFD's 13F filing for Q3 2025, filed 21 Oct 2025.